Ultracod pairs acetaminophen with codeine — two ingredients in distinct pharmacological classes — within a single oral preparation aimed at the management of moderate pain. Combination analgesics of this kind are common in many national formularies because the two ingredients act through different routes, and pairing them in a single tablet formalises a co-prescribing pattern that prescribers in several countries already use in everyday practice.
Acetaminophen is classified as an analgesic and antipyretic, while codeine belongs to the opioid class and is also recognised as an antitussive opioid. In Ultracod the two are used together for pain relief across a range of indications listed further down this page, including neuralgia, period pain, headache, toothache, and migraine. The structured indication block records the registered uses recognised by the regulators in the markets where Ultracod is sold.
Ultracod has a fairly contained regional footprint, registered in five countries that cluster across Central and Eastern Europe — the Czech Republic, Poland, Romania, Lithuania, and Latvia. Travellers familiar with the brand from this region are unlikely to find Ultracod itself in Western Europe, North America, or Asia, although acetaminophen-plus-codeine combinations exist in many other countries under different brand names, with notable variation in dosage ratios and prescription status.
Combination products that include an opioid component are regulated very differently from one country to another, and what is dispensed routinely in one market may require a stricter prescription pathway in another. A local pharmacist can confirm whether a comparable combination is registered in the destination country. Decisions about starting, continuing, or substituting a codeine-containing analgesic belong with a healthcare provider who knows the patient's history.
None known.
None.
Pharmacotherapeutic group: Other Analgesics and Antipyretics, ATC code: N02B.
Ultracod has analgesic and antipyretic actions.
Codeine is a centrally acting weak analgesic. Codeine exerts its effect through μ opioid receptors, although codeine has low affinity for these receptors, and its analgesic effect is due to its conversion to morphine. Codeine, particularly in combination with other analgesics such as paracetamol, has been shown to be effective in acute nociceptive pain.
Not applicable.
None.
Ultracod is used for the management of pain across several specific indications, including neuralgia, period pain, headache, toothache, and migraine. The combination of an analgesic-antipyretic ingredient with an opioid analgesic is intended for situations where pain relief benefits from two different mechanisms acting together. The structured indication section below this introduction lists each registered use in the markets where Ultracod is sold.
Ultracod contains two active ingredients: acetaminophen, classified as an analgesic and antipyretic, and codeine, an opioid that also has antitussive properties. Both molecules circulate worldwide under numerous brand names as single-ingredient products, and acetaminophen-plus-codeine combinations are also sold in various countries under other brand names, with regulatory status and dosage ratios differing between markets.
Ultracod is registered in five countries, all within Central and Eastern Europe: the Czech Republic, Poland, Romania, Lithuania, and Latvia. Outside this regional cluster the brand is not generally encountered, although combinations of acetaminophen and codeine exist elsewhere under different brand names. If your country is not on this list, a local pharmacist can advise on whether a comparable product is available locally.
Acetaminophen-plus-codeine combinations are sold under several brand names internationally, with variation in the ratio between the two ingredients and in prescription status. Single-ingredient acetaminophen and single-ingredient codeine products are also widely available, and other opioid analgesics within the broader class exist as well. To identify a regional equivalent, search the active ingredients on Pill2Trip or ask a pharmacist in your country.
Yes. Ultracod contains an opioid component, and combination products of this kind are regulated very differently from country to country — what is dispensed routinely in one market may require a stricter prescription pathway, or be unavailable, in another. This matters particularly for travellers carrying medication across borders. Any decision about starting, continuing, or substituting a codeine-containing analgesic should involve a healthcare provider familiar with the patient.
